Amarin | AMRN - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -5.94B 721M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Amarin USD 443.62M 5.8M 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
BioCryst Pharmaceuticals USD -454.29M 99.55M 2026-06
DBV Technologies USD 160.4M 47.5M 2026-06
GlaxoSmithKline GBP 17.64B 223M 2026-06
Halozyme Therapeutics USD 143.54M 76.09M 2026-06
Heron Therapeutics USD 6.91M 2.23M 2026-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
Nektar Therapeutics USD 576.22M 486.38M 2026-03
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Novartis USD 41.95B 3.02B 2026-06